Loading company…
NXI Therapeutics develops selective immunosuppressive drugs for autoimmune diseases and organ transplantation.
NXI Therapeutics develops immunosuppressants that target coronin 1 biology to regulate T-cell responses involved in autoimmunity and graft rejection. Its approach aims to retain immune protection against infections, vaccinations and cancers. Founded in 2021, the company is based in Basel, Switzerland. In June 2024, it received grant funding from InnoBooster as part of a larger CHF 3.5 million equity and grant funding round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in